These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26333236)

  • 1. Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?
    Kesselheim AS; Darrow JJ
    Yale J Health Policy Law Ethics; 2015; 15(2):293-347. PubMed ID: 26333236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muddying the waters: how the Supreme Court's decision in Merck v. Integra fails to resolve problems of judicial interpretation of 35 U.S.C. Section 271(E)(1), the "safe harbor" provision of the Hatch-Waxman Act.
    Sertic M
    Health Matrix Clevel; 2007; 17(2):377-439. PubMed ID: 18326397
    [No Abstract]   [Full Text] [Related]  

  • 3. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 5. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 6. Access before approval--a right to take experimental drugs?
    Okie S
    N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
    [No Abstract]   [Full Text] [Related]  

  • 7. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box.
    Khullar D; Ohn JA; Trusheim M; Bach PB
    N Engl J Med; 2020 Jan; 382(5):473-480. PubMed ID: 31995697
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview of the Hatch-Waxman Act and its impact on the drug development process.
    Mossinghoff GJ
    Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
    [No Abstract]   [Full Text] [Related]  

  • 9. The ongoing regulation of generic drugs.
    Frank RG
    N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract]   [Full Text] [Related]  

  • 10. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hatch-Waxman Act: balancing competing interests or survival of the fittest?
    Behrendt KE
    Food Drug Law J; 2002; 57(2):247-71. PubMed ID: 12436990
    [No Abstract]   [Full Text] [Related]  

  • 12. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The History and Political Economy of the Hatch-Waxman Amendments.
    Lietzan E
    Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 16. A new history and discussion of 180-day exclusivity.
    Korn DE; Lietzan E; Scott SW
    Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific and legal viability of follow-on protein drugs.
    Dudzinski DM; Kesselheim AS
    N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
    [No Abstract]   [Full Text] [Related]  

  • 18. Correcting Hatch-Waxman.
    Fernandes M
    Health Aff (Millwood); 2008; 27(3):902-3; author reply 903. PubMed ID: 18475000
    [No Abstract]   [Full Text] [Related]  

  • 19. Teva v. Eisai: what's the real "controversy"?
    Wang GL
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.